Exelixis Inc. (EXEL)
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Exelixis' stock has surged over 45% since my "Sell" rating given in March last year, driven by strong performance of cabozantinib, which remains a leading TKI for various cancers. Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses. Exelixis is optimistic about new approvals for cabozantinib in neuroendocrine tumors and has promising pipeline assets besides zanzalintinib in various cancer indications.
No FDA advisory meeting for Exelixis a positive, says Citi
Citi keeps a Buy rating on Exelixis with a $38 price target after the company announced that it has been notified by the FDA that the application for Cabometyx for the treatment of previously treated advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors will no longer be a subject of discussion at the March oncologic drugs advisory committee meeting. "While no specific information on the catalyst has been disclosed, we view the shift as positive," the analyst tells investors in a research note. The firm expects the FDA determined there is no need for the panel given the strength in Cabometyx's CABINET dataset. The firm highlights that the FDA action date remains scheduled for April 3.
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
Exelixis downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Exelixis to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis has played out positively," as a judge ruled in the MSN II litigation case for cabozantinib patents, ruling that Exelixis' '349 patent is not invalid but that MSN's ANDA is not infringing, notes the analyst, who now sees limited upside to the story in 2025 beyond zanzalintinib's readout in colorectal cancer. The firm has raised its target on zanzalintinib's probability of success in CRC, which it now pegs at 50%, but views the success of the trial as "a toss-up" given the history of cabometyx's combination with Tecentriq in this indication, the analyst added.
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL or INCY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
